Cargando…
Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association for the Study of the Liver
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641574/ https://www.ncbi.nlm.nih.gov/pubmed/32971587 http://dx.doi.org/10.3350/cmh.2020.0264 |
| _version_ | 1783605944916115456 |
|---|---|
| author | Patoulias, Dimitrios Doumas, Michael |
| author_facet | Patoulias, Dimitrios Doumas, Michael |
| author_sort | Patoulias, Dimitrios |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7641574 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | The Korean Association for the Study of the Liver |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76415742020-11-13 Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”? Patoulias, Dimitrios Doumas, Michael Clin Mol Hepatol Letter to the Editor The Korean Association for the Study of the Liver 2020-10 2020-09-25 /pmc/articles/PMC7641574/ /pubmed/32971587 http://dx.doi.org/10.3350/cmh.2020.0264 Text en Copyright © 2020 by The Korean Association for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Editor Patoulias, Dimitrios Doumas, Michael Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”? |
| title | Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”? |
| title_full | Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”? |
| title_fullStr | Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”? |
| title_full_unstemmed | Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”? |
| title_short | Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”? |
| title_sort | lean non-alcoholic fatty liver disease: is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”? |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641574/ https://www.ncbi.nlm.nih.gov/pubmed/32971587 http://dx.doi.org/10.3350/cmh.2020.0264 |
| work_keys_str_mv | AT patouliasdimitrios leannonalcoholicfattyliverdiseaseisthereaplacefornovelantidiabeticsinthetherapeuticmanagementofthisunderappreciatedenemy AT doumasmichael leannonalcoholicfattyliverdiseaseisthereaplacefornovelantidiabeticsinthetherapeuticmanagementofthisunderappreciatedenemy |